Evidence map›Paper›PMID 34282342›Full record

ReviewNature reviews. Nephrology2021

Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function.

Eoin Brennan, Phillip Kantharidis, Mark E Cooper, Catherine Godson

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 4 pooled it
20.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 4 syntheses or guidelines pooled it, 252 citations in OpenAlex.

  1. Pooled it
  2. Lipid homeostasis in diabetic kidney disease.International journal of biological sciences · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Omega-3 fatty acids reprogram tumor-associated macrophage cytokine signaling and suppress pancreatic cancer growth.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Eoin BrennanDiabetes Complications Research Centre, Conway Institute and School of Medicine, University College Dublin, Dublin, Ireland. eoin.brennan@ucd.ie.ORCID http://orcid.org/0000-0003-4908-5474
Phillip KantharidisDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Mark E CooperDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-5953-642X
Catherine GodsonDiabetes Complications Research Centre, Conway Institute and School of Medicine, University College Dublin, Dublin, Ireland. catherine.godson@ucd.ie.
Monash University · AUUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity, diabetes mellitus, hypertension and cardiovascular disease are risk factors for chronic kidney disease (CKD) and kidney failure. Chronic, low-grade inflammation is recognized as a major pathogenic mechanism that underlies the association between CKD and obesity, impaired glucose tolerance, insulin resistance and diabetes, through interaction between resident and/or circulating immune cells with parenchymal cells. Thus, considerable interest exists in approaches that target inflammation as a strategy to manage CKD. The initial phase of the inflammatory response to injury or metabolic dysfunction reflects the release of pro-inflammatory mediators including peptides, lipids and cytokines, and the recruitment of leukocytes. In self-limiting inflammation, the evolving inflammatory response is coupled to distinct processes that promote the resolution of inflammation and restore homeostasis. The discovery of endogenously generated lipid mediators - specialized pro-resolving lipid mediators and branched fatty acid esters of hydroxy fatty acids - which promote the resolution of inflammation and attenuate the microvascular and macrovascular complications of obesity and diabetes mellitus highlights novel opportunities for potential therapeutic intervention through the targeting of pro-resolution, rather than anti-inflammatory pathways.

Indexed as

Lipid MetabolismLipidsDiabetes MellitusDiabetic AngiopathiesDiabetic NephropathiesHumansInflammationInflammation MediatorsKidneyObesityRenal Insufficiency, ChronicInflammation MediatorsLipids

Identifiers

PMID34282342
PMCPMC8287849
OpenAlexW3186721658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.